anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
SEGLENTIS study on acute pain after bunionectomy with osteotomy

The efficacy and safety of SEGLENTIS was evaluated in one randomized, double-blind, parallel group study comparing SEGLENTIS to tramadol, celecoxib, and placebo (NCT03108482). The study enrolled 637 patients 18 years of age or older (age ranged between 18 and 77) with acute post-operative pain (≥5 and ≤9 on a 0-10 Numeric Pain Rating Scale [NPRS]) following unilateral first metatarsal osteotomy with internal fixation. Patients were randomized at a ratio of 2:2:2:1 to SEGLENTIS 200 mg every 12 hours, tramadol 50 mg every 6 hours, celecoxib 100 mg every 12 hours, or placebo in a double-blind, double-dummy study. Use of rescue medication (acetaminophen and oxycodone HCl) was permitted during the study. Patients had a mean baseline pain intensity of 6.7 on the NPRS.

The primary efficacy endpoint was time-weighted summed pain intensity difference over 48 hours (SPID48). Patients in the SEGLENTIS group had statistically significantly better mean SPID48 scores than any of the other groups after bunionectomy. Pain intensity difference from baseline over 48 hours mean values by treatment group are shown in Figure 1.

Figure 1: Pain Intensity Difference by Evaluation Time Point from Baseline to 48 hours – Post Operative Bunionectomy with Osteotomy (Full Analysis Set Population)
Among patients with chronic infection with hepatitis B virus or hepatitis C virus, evaluation of the stage of liver fibrosis is of major importance for determining prognosis and therapeutic decisions. Liver biopsy is a costly and invasive technique with associated mortality and morbidity. A typical biopsy fragment represents only 1/50,000 of the organ. Several noninvasive radiological techniques have been investigated for the diagnosis of liver fibrosis and cirrhosis. Diffusion-weighted magnetic resonance imaging (DW-MRI) is a particularly appealing method for the diagnosis of liver fibrosis. Because it is easy to implement, non-operator dependent, and process without the need for contrast agents. However, preliminary studies on small numbers of patients in which various hardware and sequencing profiles were used have reported inconsistent results for staging liver fibrosis with DW-MRI. The aims of this study are to evaluate correlation between stage of hepatic fibrosis and liver apparent diffusion coefficient (ADC) and normalized liver ADC with spleen assessed by DW-MRI in patients with chronic viral hepatitis B or C. Also, this study aim to evaluate factors that influence liver ADC and normalized liver ADC with spleen value for predicting the stage of liver fibrosis as well as to estimate the optimal cutoff values of DW-MRI for determining significant liver fibrosis (fibrosis stage ≥2) and advanced fibrosis (fibrosis stage ≥3).
The efficacy of RAYOS in the treatment of rheumatoid arthritis was assessed in one multicenter, double-blind, placebo-controlled, randomized, 12-week trial in patients ≥ 18 years with active rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR) criteria. Patients were enrolled who were not currently treated with corticosteroids but had received non-biologic DMARD therapy for at least 6 months before receipt of study medication, and had an incomplete response to DMARD therapy alone. Patients were randomized in a 2:1 ratio to treatment with RAYOS 5 mg (n = 231) or placebo (n = 119) administered at 10 pm. A total of 350 patients were enrolled and ranged in age from 27 to 80 years (median age 57 years) with 84% females. Race was distributed as follows: 98% Caucasian, 1% African-American, and < 1% Asian.

The percentage of patients with improvement in rheumatoid arthritis at 12 weeks using ACR response criteria (ACR20) was assessed as the primary endpoint, and ACR20, ACR50 and ACR70 responses for patients treated with RAYOS 5 mg versus placebo are shown in Table 1. The relative efficacy of RAYOS compared to immediate-release prednisone has not been established.

The results of the components of the ACR response criteria are shown in Table 2.

The percentage of patients achieving ACR20 responses by visit is shown in Figure 2.

The percent change from baseline in the duration of morning stiffness at 12 weeks was assessed as a prespecified secondary endpoint. Patients treated with RAYOS had a median decrease in the duration of morning stiffness of 55% compared to 33% in placebo-treated patients (20% estimated median difference between treatment groups with 95% confidence interval [7, 32]). This corresponds to a median duration of morning stiffness of 46 minutes in the RAYOS group and 85 minutes in the placebo group.
Study volunteers will listen to an audio recording of the Natural History of Selborne across each session.This 4 session sequence is meant to match features of the experimental meditation sessions, including attention to the recording, room setting, social support, conditioning, and time elapsed during the sessions. We do not expect that this group will demonstrate significant blood oxygenation changes as a function of the intervention.
Tissue ecosystems are cellular communities that maintain set points through a network of intercellular interactions. We position health and chronic inflammatory disease as alternative stable set points that are (1) robust to perturbation and (2) capable of adaptation and memory. Inflammatory memory, which is the storage of prior experience to durably influence future responsiveness, is central to how tissue ecosystems may be pushed past tipping points that stabilize disease over health. Here, we develop a reductionist framework of circuit motifs that recur in tissue set points. In type 2 immunity, we distinctly find the emergence of 2-cell positive feedback motifs. In contrast, directional motif relays and 3-cell networks feature more prominently in type 1 and 17 responses. We propose that these differences guide the ecologic networks established after surpassing tipping points and associate closely with therapeutic responsiveness. We highlight opportunities to improve our current knowledge of how circuit motifs interact when building toward tissue-level networks across adaptation and memory. By developing new tools for circuit motif nomination and applying them to temporal profiling of tissue ecosystems, we hope to dissect the stability of the chronic inflammatory set point and open therapeutic avenues for rewriting memory to restore health.
Stereotactic neoadjuvant ablative radiation give in three doses of 10 Gy (30 Gy given in 3 fractions, one treatment every second business day). Lumpectomy to follow within 14-20 days from last radiation treatment.
Disclosed is a tape preparation comprising etodolac in an ionic liquid form, which has high transdermal absorbability. Etodolac is reacted with an organic amine compound to produce an ionic liquid of etodolac. By using the ionic liquid, it becomes possible to increase the transdermal absorbability of etodolac. Further for the purpose of enhancing the transdermal absorbability and the tissue penetration ability of an ionic solution of etodolac, the composition of an organic solvent system for the ionic solution of etodolac is investigated, and it is found that a mixed solvent of an alcohol and an ester (1:2 to 2:1) is suitable as the organic solvent. Still further, an appropriate adhesion force can be achieved by properly selecting a softening agent. In this manner, a tape preparation having good transdermal absorbability can be prepared. The tape preparation can exert its pharmacological efficacy rapidly, and is therefore extremely effective for the teatment of a chronic pain such as rheumatoid arthritis, osteoarthritis and lumbago, an inflammatory diseases such as shoulder periarthritis and tendovaginitis, cervical syndrome, a pain induced by a surgery or an injury, or the like.
Lixisenatide 10 micrograms. Subcutaneous injection administered once.
The present invention relates to a novel eye-drop solution that has superior microbe and bacteria management properties. Regular use in the eye will prevent bacteria from being attached to the eye. Regular use of the eye-drops will also prevent growth of microbes in the eye. A patient that uses this invention can slow the progression of infection and growth of microbes between cleaning. For disposable contact lenses the antimicrobial management properties reduces the risk of infection during the extended wear period. In one embodiment, there is a method of treating contact lenses comprising administering to the lens an ophthalmically safe composition comprising an amount of antimicrobial agent that prevents growth of microbes in the eye but is a less than the minimum disinfecting amount.
Mycophenolate Mofetil, USP is an antimetabolite immunosuppressant. It is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent; inosine monophosphate dehydrogenase (IMPDH) inhibitor.

The chemical name for mycophenolate mofetil (MMF) is 2-morpholinoethyl (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate. It has an empirical formula of C23H31NO7, a molecular weight of 433.50, and the following structural formula:

MMF is a white to off-white crystalline powder. It is slightly soluble in water (43 µg/mL at pH 7.4); the solubility increases in acidic medium (4.27 mg/mL at pH 3.6). It is freely soluble in acetone, soluble in methanol, and sparingly soluble in ethanol. The apparent partition coefficient in 1-octanol/water (pH 7.4) buffer solution is 238. The pKa values for MMF are 5.6 for the morpholino group and 8.5 for the phenolic group.

MMF hydrochloride has a solubility of 65.8 mg/mL in 5% Dextrose Injection USP (D5W). The pH of the reconstituted solution is 2.4 to 4.1.

Mycophenolate Mofetil, USP is available for oral administration as capsules containing 250 mg of mycophenolate Mofetil, USP and tablets containing 500 mg of mycophenolate Mofetil, USP.

Inactive ingredients in Mycophenolate mofetil capsules USP, 250 mg include microcrystalline cellulose, hydroxypropyl cellulose, povidone (K-90), croscarmellose sodium, talc and magnesium stearate. The capsule shells contain FD&C blue #2, gelatin, red iron oxide, sodium lauryl sulfate, titanium dioxide and yellow iron oxide. The imprinting ink contains shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, iron oxide black and potassium hydroxide.

Mycophenolate Mofetil Capsules, USP meets USP Dissolution Test 2. 

Inactive ingredients in Mycophenolate Mofetil USP, 500 mg tablets include Microcrystalline cellulose, Povidone, Croscarmellose sodium and Magnesium stearate. The film coating contains Hypromellose, Titanium dioxide, Polyethylene glycol, Iron oxide red, FD&C blue#2 aluminium lake and black iron oxide.

Mycophenolate Mofetil Tablets, USP meets USP Dissolution Test 2.
Sepsis remains a great challenge for clinicians, early goal-directed therapy(EGDT), referring to a number of target-achieving indicators including systemic central venous oxygen saturation(ScvO2) after initial fluid resuscitation within 6 hours, has been one of the main treatment for sepsis. ScvO2 is the only indicator that reflects tissue oxygen metabolism. However, there're studies confirmed that ScvO2 oriented EGDT cannot reduce the mortality of sepsis. So it is important to find out a more effective indicator. Lactic acid is a product of anaerobic metabolism of the body, lactate clearance has been found to effectively predict the prognosis of sepsis. Few studies have shown that lactate clearance oriented fluid resuscitation can be of benefit in patients with sepsis. Nevertheless, whether lactate clearance could be combined with sepsis Bundle as a new marker to improve the prognosis remains a problem. The objective of this study is to discuss the feasibility of lactate clearance oriented sepsis treatment through multi-center clinical trial.
Use of Pichia anomala extract (I) as an active principle for skin treatment. An independent claim is included for a cosmetic and/or dermopharmaceutiacal composition comprising 0.01-20% of (I). ACTIVITY : Dermatological. MECHANISM OF ACTION : Collagen I synthase stimulator; Tyrosinase inhibitor. The ability of (I) to stimulate the collagen synthase was tested in human fibroblasts. The results showed that (I) at 1% exhibited the 60% stimulation of collagen I synthase.
Based on findings from animal reproduction studies, LAGEVRIO may cause fetal harm when administered to pregnant individuals. There are no available human data on the use of LAGEVRIO in pregnant individuals to evaluate the risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; therefore, LAGEVRIO is not recommended for use during pregnancy. When considering LAGEVRIO for a pregnant individual, the prescribing healthcare provider must communicate the known and potential benefits and the potential risks of using LAGEVRIO during pregnancy to the pregnant individual. LAGEVRIO is authorized to be prescribed to a pregnant individual only after the healthcare provider has determined that the benefits would outweigh the risks for that individual patient. If the decision is made to use LAGEVRIO during pregnancy, the prescribing healthcare provider must document that the known and potential benefits and the potential risks of using LAGEVRIO during pregnancy were communicated to the pregnant individual.

Advise individuals of childbearing potential of the potential risk to a fetus and to use an effective method of contraception correctly and consistently, as applicable, during treatment with LAGEVRIO and for 4 days after the final dose [see Use in Specific Populations (8.1, 8.3 and Nonclinical Toxicology (13.1)].

Prior to initiating treatment with LAGEVRIO, assess whether an individual of childbearing potential is pregnant or not, if clinically indicated. Pregnancy status does not need to be confirmed in patients who have undergone permanent sterilization, are currently using an intrauterine system or contraceptive implant, or in whom pregnancy is not possible. In all other patients, assess whether the patient is pregnant based on the first day of last menstrual period in individuals who have regular menstrual cycles, is using a reliable method of contraception correctly and consistently or have had a negative pregnancy test. A pregnancy test is recommended if the individual has irregular menstrual cycles, is unsure of the first day of last menstrual period or is not using effective contraception correctly and consistently [see Box].
Couples in the PFE condition will receive 8 sessions of standardized PTSD Family Education, a manualized psychoeducational program designed to help couples learn more about posttraumatic stress disorder and related difficulties. This psychotherapy is administered over 8 to 15 weeks and is delivered in-person in the therapist's office.
At the end of the bronchoscopy, a recruiting maneuver will be applied to the patients. Recruiting Maneuver consists in the application of an airway pressure of 30 cmH2O for a period of 30 seconds.
PURPOSE: A method for removing pigment from Centipede grass extract is provided to maintain antioxidation, skin whitening, and anti-wrinkling activities. CONSTITUTION: A Centipede grass extract having constant physiological activity without pigment is prepared by irradiating radiation to Centipede grass extract. The Centipede grass extract is isolated using water, alcohol, or mixture thereof from the dried leaves of Centipede grass. The alcohol is C1-C4 alcohol. The radiation is gamma ray, electronic beam, UV, or X ray. The pigment is cyanidin-3-O-glucoside or malvidin-3-(6-acetoyl)glucoside. A cosmetic composition for antioxidation, skin whitening, and anti-wrinkling contains the Centipede grass extract as an active ingredient.
Described herein are oral compositions comprising a film, wherein the film comprises a dye entrapped in a silica sol-gel. Described herein are oral compositions comprising a film, wherein the film comprises a dye entrapped in a silica sol-gel. Provided is a consumer to industrial scale energy trigeneration process based microgrid combined cooling, heat and power. The present invention includes conversion, processing, extraction and/or storage systems for electrical, chemical and thermal energy. The invention provides a quintessential renewable energy ecosystem incorporating vital energy generation, thermal heating and cooling processes with integrated components installed to encompass a distributed renewable energy generation, energy storage and integrated automation system. The automation system of the invention provides the ability to view, monitor, analyze, control and interact with system components.
PROBLEM TO BE SOLVED: To obtain a therapeutic and prophylactic agent for atopic dermatitis containing an essence of plant bodies of a labiate catnip. SOLUTION: This therapeutic and prophylactic agent for atopic dermatitis contains pulverized, chopped and dried plant bodies of a labiate catnip, an extract separated from the processed material with a solvent (e.g. water or an alcohol) or a substance removed from the solvent and an essence which is a fractionated substance thereof as an active ingredient. The extraction is performed by adding the solvent in an amount of 1-20 times based on the plant bodies or their processed material thereto, then dipping the plant bodies, etc., therein at ambient temperature for several days or at a temperature near the boiling point of the solvent for several hours and, as necessary, subsequently removing an insoluble substance.  The extract is formulated into an oral administration agent, a parenteral injection or a percutaneous administration agent by further suitably blending optional ingredients therewith. The daily dose for an adult is 5-500mg divided into several portions in the case of the oral administration agent and 1-100mg for the parenteral injection. When the resultant formulation is percutaneously administered as a dermal preparation for external use, 0.01-10wt.% is blended in the dosage form and a proper amount thereof is daily applied to a lesion several times.
PURPOSE: To obtain a therapeutic agent for pancreatitis, containing a phosphoric diester of ascorbic acid with tocopherol, having inhibiting actions on pancreatic phosholipase A2 and low toxicity and excellent in safety. CONSTITUTION: This therapeutic agent for pancreatitis contains a phosphoric diester of the formula (R1 and R2 are each H or methyl), e.g. L-ascorbic acid or DL-α-tocopherol phosphoric diester potassium. The agent can orally or parenterally be administered and the daily dose thereof is preferably, e.g. about 1-100mg for an adult at a time in the case of a parenteral injection and about 10-1000mg for an adult at a time several times in the case of a medicine for internal use. The therapeutic agent has better therapeutic effects than those of camostat mesilate which is a commercially available therapeutic agent for pancreatitis.
Constitution of Teflaro Powder for Injection

Aseptic technique must be followed in preparing the infusion solution. The contents of Teflaro vial should be constituted with 20 mL Sterile Water for Injection, USP; or 0.9% of sodium chloride injection; or 5% of dextrose injection; or lactated ringer’s injection. Constitution time is less than 2 minutes. Mix gently to constitute and check to see that the contents have dissolved completely. The preparation of Teflaro solutions is summarized in Table 5. 

* The recommended dosage of Teflaro is based on the age and weight of the child. See Table 2

Dilution of the Constituted Solution of Teflaro

The constituted solution must be further diluted in a range between 50 mL to 250 mL before intravenous infusion into patients. Use the same diluent used for constitution of the powder for this further dilution, unless sterile water for injection was used earlier. If sterile water for injection was used earlier, then appropriate infusion solutions include: 0.9% Sodium Chloride Injection, USP; 5% Dextrose Injection, USP; 2.5% Dextrose Injection, USP, and 0.45% Sodium Chloride Injection, USP; or Lactated Ringer’s Injection, USP. 

Dilution of the Constituted Solution of Teflaro in the 50 mL Infusion Bags Only

Preparation of 600 mg of Teflaro dose in 50 mL infusion bag (for adult patients): Withdraw 20 mL of diluent from the infusion bag. Proceed to inject entire content of the Teflaro vial into the bag to provide a total volume of 50 mL. The resultant concentration is approximately 12 mg/mL.

Preparation of 400 mg of Teflaro dose in 50 mL infusion bag (for adult patients or pediatric patients weighing > 33 kg): Withdraw 20 mL of diluent from the infusion bag. Proceed to inject entire content of the Teflaro vial into the bag to provide a total volume of 50 mL. The resultant concentration is approximately 8 mg/mL.

Preparation of Teflaro dose in the infusion bag (for pediatric patients weighing ≤ 33 kg): The amount of solution withdrawn from the constituted Teflaro vial for pediatric patients weighing < 33 kg for dilution in the infusion bag will vary according to the weight and age of the child. The infusion solution concentration for administration should not exceed 12 mg/ml ceftaroline fosamil. Discard unused portion.

The color of Teflaro infusion solutions ranges from clear, light to dark yellow depending on the concentration and storage conditions. When stored as recommended, the product potency is not affected. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.